EMA Authorised: Naveruclif (paclitaxel) — Accord Healthcare S.L.U.

View source ↗

Summary

EMA authorised Naveruclif (paclitaxel) by Accord Healthcare S.L.U. for breast cancer, pancreatic cancer, and non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Non-small Cell Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• Naveruclif (paclitaxel)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms;Pancreatic Neoplasms;Carcinoma, Non-Small-Cell Lung. MAH: Accord Healthcare S.L.U.. Decision date: 11/08/2025